A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
Phase of Trial: Phase I/II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs DS 1040 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms ASSENT
- Sponsors Daiichi Sankyo Inc
- 10 Jun 2017 Biomarkers information updated
- 25 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 25 Aug 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.